Sympathomodulation in Heart Failure with High vs. Normal Ejection Fraction

BACKGROUND: Despite recent advances in the treatment of heart failure with preserved ejection fraction (HFpEF), the overall outcome is poor and evidence-based therapeutic options are scarce. So far, the only evidence-based therapy in HFpEF, sodium glucose linked transporter 2 inhibitors, has only in...

Descripción completa

Detalles Bibliográficos
Autores principales: Fengler, Karl, Kresoja, Karl-Patrik, Rommel, Karl-Philipp, Rosch, Sebastian, Roeder, Maximilian v., Desch, Steffen, Thiele, Holger, Lurz, Philipp
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier 2022
Materias:
Original Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10242566/
https://www.ncbi.nlm.nih.gov/pubmed/37288333
http://dx.doi.org/10.1016/j.shj.2022.100073

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10242566/
https://www.ncbi.nlm.nih.gov/pubmed/37288333
http://dx.doi.org/10.1016/j.shj.2022.100073

Ejemplares similares